Georgiy I. Gafton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Georgiy I. Gafton has a total of 180 co-authors. Here are the top co-authors by number of shared publications:
- Evgeniy V. Levchenko
Department of Thoracic Oncology, N. N. Petrov National Medical Research Center of Oncology, Sankt-Petersburg, Russia
3 shared publications G I Gafton
3 shared publicationsV A Kochnev
3 shared publicationsV G Lemekhov
3 shared publicationsV G Petrov
3 shared publicationsV V Anisimov
3 shared publications
Latest Publications
- 25 September 2026
- Published by Publishing House ABV Press in Supportive Therapy in Oncology
- Vol. 3 (2-3)
Functional results after radical treatment of osteosarcoma in children. Experience of the N.N. Petrov National Medical Research Center of Oncology
Background. Bone reconstruction using an endoprosthesis after tumor removal aims to quickly restore mobility, relieve pain, achieve body stability, and improve overall quality of life. Physical activity defined as any movement requiring energy is assessed using subjective instruments (questionnaires) and objective methods (e.g., accelerometers). Aim. To evaluate functionality of the limbs after endoprosthetic reconstruction in children with osteosarcoma. Materials and methods. Four patients aged 11 to 17 years were assessed for limb function 1 year after endoprosthesis. The control group consisted of 4 healthy children. Two scales, Musculo-Skeletal Tumor Society (MSTS) and Toronto Extremity Salvage Score (TESS), were used to analyze functional outcomes after oncological endoprosthesis. Results. Patients who underwent knee surgery showed limited range of motion: right knee flexion angle was 86.7 ± 25.6°, left was 85 ± 25.8°, while in the control group these values were significantly higher (137.6 ± 13.2°). The extension angle was 0 in both groups. The difference in range of motion was statistically significant (p = 0). Muscle strength was reduced in patients who underwent surgery. The strength of the right knee flexors was 11.4 ± 2.8 kg, of extensors 11.9 ± 3.1 kg, which is significantly lower than in the control group (21.9 ± 5.4 kg and 27.6 ± 5.5 kg, respectively). Similar results were observed in the left leg: flexor strength was 11.8 ± 2.9 kg, extensor strength was 10.7 ± 1.9 kg versus 21.5 ± 4.3 kg and 25.4 ± 3.6 kg in the control group. The differences in muscle strength were statistically significant (p = 0). In the endoprosthesis group, sway speed when moving from a sitting to a standing position was higher than in the control group (4.1 ± 1.5°/s versus 2.8 ± 1.1°/s; p = 0.005). However, walking speed was lower (70.8 ± 8.9 cm/s versus 79.55 ± 10.94 cm/s in the control group; p = 0.005). Time to rise and overcome an obstacle was increased in the endoprosthesis group (2.7 ± 0.6 s versus 1.6 ± 0.3 s). There were cases of unsuccessful test performance. There was no significant correlation between MSTS and TESS scores and range of motion, but a nonsignificant positive correlation with muscle strength was observed. A positive correlation was found between MSTS and TESS scores and movement speed and daily energy expenditure (r = 0.56; p = 0.045). Muscle strength was positively associated with postural stability and daily energy expenditure. Conclusion. An objective assessment allows comparison of various surgical techniques and refinement of rehabilitation plans. Ultimately, this contributes to improved overall well-being and life expectancy of the patients.
- 25 September 2026
- Published by Publishing House ABV Press in Supportive Therapy in Oncology
- Vol. 3 (2-3)
Functional results after radical treatment of osteosarcoma in children. Experience of the N.N. Petrov National Medical Research Center of Oncology
Background. Bone reconstruction using an endoprosthesis after tumor removal aims to quickly restore mobility, relieve pain, achieve body stability, and improve overall quality of life. Physical activity defined as any movement requiring energy is assessed using subjective instruments (questionnaires) and objective methods (e.g., accelerometers). Aim. To evaluate functionality of the limbs after endoprosthetic reconstruction in children with osteosarcoma. Materials and methods. Four patients aged 11 to 17 years were assessed for limb function 1 year after endoprosthesis. The control group consisted of 4 healthy children. Two scales, Musculo-Skeletal Tumor Society (MSTS) and Toronto Extremity Salvage Score (TESS), were used to analyze functional outcomes after oncological endoprosthesis. Results. Patients who underwent knee surgery showed limited range of motion: right knee flexion angle was 86.7 ± 25.6°, left was 85 ± 25.8°, while in the control group these values were significantly higher (137.6 ± 13.2°). The extension angle was 0 in both groups. The difference in range of motion was statistically significant (p = 0). Muscle strength was reduced in patients who underwent surgery. The strength of the right knee flexors was 11.4 ± 2.8 kg, of extensors 11.9 ± 3.1 kg, which is significantly lower than in the control group (21.9 ± 5.4 kg and 27.6 ± 5.5 kg, respectively). Similar results were observed in the left leg: flexor strength was 11.8 ± 2.9 kg, extensor strength was 10.7 ± 1.9 kg versus 21.5 ± 4.3 kg and 25.4 ± 3.6 kg in the control group. The differences in muscle strength were statistically significant (p = 0). In the endoprosthesis group, sway speed when moving from a sitting to a standing position was higher than in the control group (4.1 ± 1.5°/s versus 2.8 ± 1.1°/s; p = 0.005). However, walking speed was lower (70.8 ± 8.9 cm/s versus 79.55 ± 10.94 cm/s in the control group; p = 0.005). Time to rise and overcome an obstacle was increased in the endoprosthesis group (2.7 ± 0.6 s versus 1.6 ± 0.3 s). There were cases of unsuccessful test performance. There was no significant correlation between MSTS and TESS scores and range of motion, but a nonsignificant positive correlation with muscle strength was observed. A positive correlation was found between MSTS and TESS scores and movement speed and daily energy expenditure (r = 0.56; p = 0.045). Muscle strength was positively associated with postural stability and daily energy expenditure. Conclusion. An objective assessment allows comparison of various surgical techniques and refinement of rehabilitation plans. Ultimately, this contributes to improved overall well-being and life expectancy of the patients.
- Open Access
- 22 April 2026
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 18 (1) , 21-30
History of joint replacement
The article presents the history of the development of prosthetic joints. After pioneering work using ivory and metal for prosthetics, reconstruction became a significant achievement and attempts to replace all major joints were documented. An expanded understanding of the processes and basic principles implemented in modern prostheses can become the basis for further improving their functional characteristics and service life, as well as for increasing the level of care provided and the degree of patient satisfaction.
- 22 April 2026
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 18 (1) , 21-30
Open AccessHistory of joint replacement
The article presents the history of the development of prosthetic joints. After pioneering work using ivory and metal for prosthetics, reconstruction became a significant achievement and attempts to replace all major joints were documented. An expanded understanding of the processes and basic principles implemented in modern prostheses can become the basis for further improving their functional characteristics and service life, as well as for increasing the level of care provided and the degree of patient satisfaction.
- Open Access
- 11 September 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (4)
Vascular Reconstruction in Patients with Soft Tissue Sarcomas: Experience of N.N. Petrov National Medical Research Center of Oncology
Введение. Саркомы мягких тканей — редкая и гетерогенная группа опухолей. Инвазия в кровеносные сосуды описана в 5 % случаев сарком мягких тканей, что ранее было показанием к проведению калечащих операций. Благодаря внедрению различных методов пластической и реконструктивной хирургии, показания к конечность-сохраняющим операциям возрастают. Материалы и методы. 12 пациентов в период с 1 июня 2020 г. по 1 декабря 2024 г. получили лечение в НМИЦ онкологии им. Н.Н. Петрова с саркомами мягких тканей в объеме: удаление опухоли мягких тканей конечности с резекцией магистральных сосудов с реконструкцией артерии. Результаты. Операции выполнены на верхней конечности в 4 (33,3 %) случаях, на нижней конечности — в 8. В 6 случаях выполнена резекция только артерии, в 6 случаях — резекция артерии и вены, при этом восстановление целостности венозного русла не производилось. В 11 случаях для реконструкции сосудистого русла использовалась аутовена пораженной конечности, в 1 случае использована большая подкожна вена с контралатеральной конечности. Случаев тромбоза протезированной артерии, как в раннем послеоперационном периоде, так и при дальнейшем наблюдении за пациентами, не зафиксировано. Средний показатель по этой шкале составил 80 %, что соответствует хорошим результатам. Выводы. Вовлечение сосудистых структур не является абсолютным показанием для проведения калечащей операции при саркомах мягких тканей, но для оптимизации результатов лечения необходимо соответствующее планирование и определение тактики в условиях референсного центра.
- 11 September 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (4)
Open AccessVascular Reconstruction in Patients with Soft Tissue Sarcomas: Experience of N.N. Petrov National Medical Research Center of Oncology
Введение. Саркомы мягких тканей — редкая и гетерогенная группа опухолей. Инвазия в кровеносные сосуды описана в 5 % случаев сарком мягких тканей, что ранее было показанием к проведению калечащих операций. Благодаря внедрению различных методов пластической и реконструктивной хирургии, показания к конечность-сохраняющим операциям возрастают. Материалы и методы. 12 пациентов в период с 1 июня 2020 г. по 1 декабря 2024 г. получили лечение в НМИЦ онкологии им. Н.Н. Петрова с саркомами мягких тканей в объеме: удаление опухоли мягких тканей конечности с резекцией магистральных сосудов с реконструкцией артерии. Результаты. Операции выполнены на верхней конечности в 4 (33,3 %) случаях, на нижней конечности — в 8. В 6 случаях выполнена резекция только артерии, в 6 случаях — резекция артерии и вены, при этом восстановление целостности венозного русла не производилось. В 11 случаях для реконструкции сосудистого русла использовалась аутовена пораженной конечности, в 1 случае использована большая подкожна вена с контралатеральной конечности. Случаев тромбоза протезированной артерии, как в раннем послеоперационном периоде, так и при дальнейшем наблюдении за пациентами, не зафиксировано. Средний показатель по этой шкале составил 80 %, что соответствует хорошим результатам. Выводы. Вовлечение сосудистых структур не является абсолютным показанием для проведения калечащей операции при саркомах мягких тканей, но для оптимизации результатов лечения необходимо соответствующее планирование и определение тактики в условиях референсного центра.
- Open Access
- 3 September 2025
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 15 (3) , 11-21
Changes in clinical guidelines of 2023 and 2025 on treatment of cutaneous and mucosal melanoma
The article presents a comparative analysis of Russian clinical recommendations on treatment of melanoma of the skin and mucous membranes during a period of 2020 and 2023, as well as foreign recommendations of N CCN (National Comprehensive Cancer Network) and ESMO (European Society for Medical Oncology) of 2025. The main debatable issues related to changes on melanoma therapy in 2025 are presented for discussion. The topic of modifying the treatment of patients with melanoma with metastases in the brain is highlighted. New treatment options for patients with metastatic and unresectable (stage IIIC–D) melanoma are discussed, as well as the neoadjuvant and adjuvant therapy options for stage II–III cutaneous melanoma. Various treatment options for patients with local stage melanoma are considered. Among other, the recommendations of 2025 are supplemented with treatment options for melanoma in children.Aim. To highlight changes in clinical guidelines for treatment of melanoma of the skin and mucous membranes for use in daily clinical practice.
- 3 September 2025
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 15 (3) , 11-21
Open AccessChanges in clinical guidelines of 2023 and 2025 on treatment of cutaneous and mucosal melanoma
The article presents a comparative analysis of Russian clinical recommendations on treatment of melanoma of the skin and mucous membranes during a period of 2020 and 2023, as well as foreign recommendations of N CCN (National Comprehensive Cancer Network) and ESMO (European Society for Medical Oncology) of 2025. The main debatable issues related to changes on melanoma therapy in 2025 are presented for discussion. The topic of modifying the treatment of patients with melanoma with metastases in the brain is highlighted. New treatment options for patients with metastatic and unresectable (stage IIIC–D) melanoma are discussed, as well as the neoadjuvant and adjuvant therapy options for stage II–III cutaneous melanoma. Various treatment options for patients with local stage melanoma are considered. Among other, the recommendations of 2025 are supplemented with treatment options for melanoma in children.Aim. To highlight changes in clinical guidelines for treatment of melanoma of the skin and mucous membranes for use in daily clinical practice.
- Open Access
- 26 February 2024
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 70 (6) , 35-44
Metastatic pheochromocytoma in multiple endocrine neoplasia type 2A
Pheochromocytoma (PHEO) currently is considered to be malignant due to metastatic potential. One of the most common familial forms of PHEO is multiple endocrine neoplasia syndrome (MEN) type 2. The penetrance of PHEO in MEN2 syndrome is up to 50% of cases. It may be one- or two-sided, but metastases occur extremely rare. The fact that in majority of cases of MEN2 syndrome the source of distant metastases is medullary thyroid carcinoma (MTC) complicates differential diagnosis in case of PHEO metastasis.Isolated cases of PHEO with metastases to the lymph nodes, lungs, liver, bones, brain in MEN2 patients were described. In the available literature, we have found a description of 31 cases of metastatic PHEO in MEN2 syndrome. The available data of those cases is presented as a table in the article.We present a description of a 40-year-old woman with MEN2A syndrome (mutation of the RET proto-oncogene p.Cys634Tyr), with a history of twice-performed surgical treatment of MTC, with daily crises of arterial hypertension accompanied by vegetative symptoms, with a giant bilateral PHEO (up to 200 m on the right and up to 150 mm on the left) with synchronous large metastasis (up to 50 mm) into the pubic bone with the destruction. The patient underwent several surgeries: bilateral adrenalectomy, then a bilateral revision of the neck, removal of the right upper and right lower parathyroid glands, residual thyroid tissue, then resection of the right pubic bone with a tumor.
- 26 February 2024
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 70 (6) , 35-44
Open AccessMetastatic pheochromocytoma in multiple endocrine neoplasia type 2A
Pheochromocytoma (PHEO) currently is considered to be malignant due to metastatic potential. One of the most common familial forms of PHEO is multiple endocrine neoplasia syndrome (MEN) type 2. The penetrance of PHEO in MEN2 syndrome is up to 50% of cases. It may be one- or two-sided, but metastases occur extremely rare. The fact that in majority of cases of MEN2 syndrome the source of distant metastases is medullary thyroid carcinoma (MTC) complicates differential diagnosis in case of PHEO metastasis.Isolated cases of PHEO with metastases to the lymph nodes, lungs, liver, bones, brain in MEN2 patients were described. In the available literature, we have found a description of 31 cases of metastatic PHEO in MEN2 syndrome. The available data of those cases is presented as a table in the article.We present a description of a 40-year-old woman with MEN2A syndrome (mutation of the RET proto-oncogene p.Cys634Tyr), with a history of twice-performed surgical treatment of MTC, with daily crises of arterial hypertension accompanied by vegetative symptoms, with a giant bilateral PHEO (up to 200 m on the right and up to 150 mm on the left) with synchronous large metastasis (up to 50 mm) into the pubic bone with the destruction. The patient underwent several surgeries: bilateral adrenalectomy, then a bilateral revision of the neck, removal of the right upper and right lower parathyroid glands, residual thyroid tissue, then resection of the right pubic bone with a tumor.
- Open Access
- 7 July 2022
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 14 (2) , 36‑43
Pelvic endoprosthesis in tumor lesions: experience of N.N. Petrov National Medical Research Center of Oncology
Introduction. Oncological endoprosthesis for tumors of the pelvic bones is rare. It is associated with certain difficulties and is insufficiently investigated.The study objective is to evaluate the results of surgical treatment of patients with tumors of the pelvis performed between 2012 and 2021 at the N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia.Materials and methods. The study included 23 patients with primary and secondary tumors of the pelvic bones who underwent limb-saving surgeries with substitution of the postresection defect with an endoprosthesis between 2012 and 2021. Mean follow-up duration was 19 months.Results. The most common postoperative complication was infection of the postoperative wound (n = 8; 35 %). Mechanical complications associated with the installed metallic prosthesis were observed in 4 (17 %) patients. Function al results were evaluated after 6 months using the Musculoskeletal Tumor Society Score (MSTS). Mean score per this scale was 53 % which corresponds to satisfactory outcome.Conclusion. Patients with malignant tumors of the pelvic bones should undergo treatment only in specialized medical facilities. Patients for organ-saving therapy should be carefully selected.
- 7 July 2022
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 14 (2) , 36‑43
Open AccessPelvic endoprosthesis in tumor lesions: experience of N.N. Petrov National Medical Research Center of Oncology
Introduction. Oncological endoprosthesis for tumors of the pelvic bones is rare. It is associated with certain difficulties and is insufficiently investigated.The study objective is to evaluate the results of surgical treatment of patients with tumors of the pelvis performed between 2012 and 2021 at the N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia.Materials and methods. The study included 23 patients with primary and secondary tumors of the pelvic bones who underwent limb-saving surgeries with substitution of the postresection defect with an endoprosthesis between 2012 and 2021. Mean follow-up duration was 19 months.Results. The most common postoperative complication was infection of the postoperative wound (n = 8; 35 %). Mechanical complications associated with the installed metallic prosthesis were observed in 4 (17 %) patients. Function al results were evaluated after 6 months using the Musculoskeletal Tumor Society Score (MSTS). Mean score per this scale was 53 % which corresponds to satisfactory outcome.Conclusion. Patients with malignant tumors of the pelvic bones should undergo treatment only in specialized medical facilities. Patients for organ-saving therapy should be carefully selected.
- Open Access
- 29 June 2022
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 21 (3) , 33-41
DNA damage in peripheral blood mononuclear cells in patients with melanoma
Introduction. The incidence and mortality of malignant melanoma have increased steadily over the last decades; therefore, the development of novel diagnostic markers for malignant melanoma is of great importance. The purpose of the study was to assess whether the development of melanoma before any treatment is accompanied by the body changes and, in particular, DNA damage in the mononuclear cells of the peripheral blood of patients. Material and Methods. In 93 patients (26 men and 67 women) admitted to the N.N. Petrov National Medical Research Center of Oncology for surgical treatment of stage T1c-2a-b-3a-b4a-bN0-1 cutaneous malignant melanoma, and in 118 healthy people as a comparison group, the level of damage to DNA in peripheral blood mononuclear cells was studied using the “comet” method. All patients were divided into two groups: group 1 included 45 patients (13 men and 32 women) who were examined before a decision on treatment was made and group 2 consisted of 48 patients (13 men and 35 women) who previously underwent excision biopsy for melanoma. Results. The level of DNA damage in peripheral blood mononuclear cells, assessed by the comet assay, was found to be signifcantly higher in patients with melanoma than in the comparison group. Moreover, the increase in the level of DNA damage was similar both in patients with a primary tumor before starting any treatment and in those who previously underwent excision biopsy for melanoma. The relationship between the level of DNA damage in peripheral blood mononuclear cells and the morphological characteristics of the tumor cells was revealed. The Spearman correlation analysis showed that all parameters that determined DNA damage positively correlated with the thickness of melanoma according to the Breslow’s depth, and the percentage of DNA in the comet and the comet tail moment correlated with the stage of the disease. Conclusion. The development of cutaneous melanoma is accompanied by an increase in the level of DNA damage in peripheral blood mononuclear cells. The level of DNA damage in peripheral blood mononuclear cells refects the changes that occur in the patient’s body under the infuence of the tumor process, which may allow using this indicator as an additional criterion for the diagnosis and aggressiveness of melanoma.
- 29 June 2022
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 21 (3) , 33-41
Open AccessDNA damage in peripheral blood mononuclear cells in patients with melanoma
Introduction. The incidence and mortality of malignant melanoma have increased steadily over the last decades; therefore, the development of novel diagnostic markers for malignant melanoma is of great importance. The purpose of the study was to assess whether the development of melanoma before any treatment is accompanied by the body changes and, in particular, DNA damage in the mononuclear cells of the peripheral blood of patients. Material and Methods. In 93 patients (26 men and 67 women) admitted to the N.N. Petrov National Medical Research Center of Oncology for surgical treatment of stage T1c-2a-b-3a-b4a-bN0-1 cutaneous malignant melanoma, and in 118 healthy people as a comparison group, the level of damage to DNA in peripheral blood mononuclear cells was studied using the “comet” method. All patients were divided into two groups: group 1 included 45 patients (13 men and 32 women) who were examined before a decision on treatment was made and group 2 consisted of 48 patients (13 men and 35 women) who previously underwent excision biopsy for melanoma. Results. The level of DNA damage in peripheral blood mononuclear cells, assessed by the comet assay, was found to be signifcantly higher in patients with melanoma than in the comparison group. Moreover, the increase in the level of DNA damage was similar both in patients with a primary tumor before starting any treatment and in those who previously underwent excision biopsy for melanoma. The relationship between the level of DNA damage in peripheral blood mononuclear cells and the morphological characteristics of the tumor cells was revealed. The Spearman correlation analysis showed that all parameters that determined DNA damage positively correlated with the thickness of melanoma according to the Breslow’s depth, and the percentage of DNA in the comet and the comet tail moment correlated with the stage of the disease. Conclusion. The development of cutaneous melanoma is accompanied by an increase in the level of DNA damage in peripheral blood mononuclear cells. The level of DNA damage in peripheral blood mononuclear cells refects the changes that occur in the patient’s body under the infuence of the tumor process, which may allow using this indicator as an additional criterion for the diagnosis and aggressiveness of melanoma.
- 1 January 2021
- Published by Elsevier in Pathology - Research and Practice
- Vol. 217, 153214
Biological features of tissue and bone sarcomas investigated using an in vitro model of clonal selection
- 1 January 2021
- Published by Elsevier in Pathology - Research and Practice
- Vol. 217, 153214
Biological features of tissue and bone sarcomas investigated using an in vitro model of clonal selection
- 11 March 2019
- Published by Cifra Ltd - Russian Agency for Digital Standardization (RADS) in Тромбоз, гемостаз и реология
- No. 1,p. 43-66
The prevention and the treatment of venous thromboembolic complications in oncology (Textbook for students in higher education and in additional professional education)
Учебное пособие для обучающихся в системе высшего и дополнительного профессионального образования Учебное пособие используется для аудиторных занятий и самостоятельной работы студентов при изучении профилак- тики и лечения венозных тромбоэмболических осложнений у пациентов со злокачественными новообразованиями. Содержание освещает основные вопросы определения риска венозных тромбоэмболических осложнений и методы их профилактики и лечения у больных с местно-распространенными и метастатическими злокачественными новооб- разованиями. Учебное пособие предназначено для обучающихся в системе высшего образования (аспиранты, орди- наторы, интерны, студенты) и дополнительного профессионального образования (слушатели циклов повышения ква- лификации). Учебное пособие утверждено в качестве учебно-методического пособия Ученым советом ФГБУ «НМИЦ онкологии им. Н. Н. Петрова» МЗ РФ (протокол No 10 от 27.09.2016). ЛИТЕРАТУРА Российские клинические рекомендации по профилактике и лечению венозных тромбоэмболических осложнений у он- кологических пациентов. 2012. URL: http://www.phlebounion. ru/db.img/vte_in_oncology_final_04.05.2011.pdf. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Prac- tice Guideline Update. J Clin Oncol. 2013;31(17):2189–204. Mandala M., Falanga A., Roila F. Group EGW. Management of ve- nous thromboembolism (VTE) in cancer patients: ESMO Clin- ical Practice Guidelines. Ann Oncol. 2011;22(Suppl 6):vi85–92. Маджуга А.В., Сомонова О.В., Елизарова А.Л., Астахова В.М. ДВС-синдром в онкологии. Materia Medica. 1997;1(13):45–52. Российский Консенсус по профилактике послеоперацион- ных венозных тромбоэмболических осложнений. М.: Меди- цина, 2000. 20 с. Савельев В.С., Яблоков Ю.Г., Кириенко А.И. Тромбоэмболия легочной артерии. М.: Медицина, 1979. 264 с. Agnelli G. Venous Thromboembolism and cancer: two way clini- cal association. Thromb Haemost. 1997;78(1):117–20. Allan A., Williams J.T., Bolton J.P., LeQuesne L.P. The use of grad- uated compression stockings in the prevention ofpostoperative deep vein thrombosis. Brit J Surg. 1983;70:172–4. Bergqvist D., Burmark U.S., Flordal P.A. et al. Low molecular weight heparin started before surgery as prophylaxis against deep veine thrombosis: 2500 versus 5000 XaI units in 2070 patients. Brit J Surg. 1995;82:496–501. Chahinian A.P., Ware J.H., Zimmer U.N. Update on anticoagu- lation with warfarin and alternating chemotherapy in extensive small cell carcinoma of the lung (SCCL). Proc Am Soc Clin On- col. 1985;4:191. Kucher N., Koo S., Quiroz R. et al. Electronic Alerts to Prevent Venous Thromboembolism among Hospitalized Patients. N Engl J Med. 2005;352:969–77. Khorana A.A., Kuderer N.M., Culakova E. et al. Development and validation of a predictive model for chemotherapy-associ- ated thrombosis. Blood. 2008;111(10):4902–7. Bergqvist В., Agnelli G., Cohen A.T. et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Eng J Med. 2002;346:975–80. ENOXACAN Study Group «Efficacy and safety of Enoxaparin ver- sus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double blind randomized multicentre trial with venographic assessment». Brit J Surg. 1997;84:1099–103. FalangaA.,BarbuiT.,RicklesF.R.,LevineM.N.Guidelinesforclot- ting studies in cancer patients. Thromb Haemost. 1993;70:540–2. Gallus A.S. Prevention of post operative deep leg vein thrombosis in patients with cancer. Thromb Haemost. 1997;78:126–32. Gallus A., Cade J., Ockelford P. et al. Orgaran or heparin for prevention of venous thrombosis after elective surgery for malig- nant disease? A double blind randomized multicentre compari- son. Thromb Haemot. 1993;70:562–7. Green D., Hull R.D., Brant R., Pineo G.F. Lower mortality in cancer patients treated with low molecular weight versus standard heparin. Lancet. 1992;339(8804):1476. Green K.B., Silverstain R.L. Hypercoagulobility in cancer. Hematol Oncol Clin North Am. 1996;125:1–7. Hillen H.F. Thrombosis in cancer patients. Ann Oncol. 2000;11(Suppl 3):273–6. Kakkar V.V., Howe S.T., Nicolaides A.N. et al. Deep vein thrombosis of the leg: Is there a «high risk» group. Amer J Surg. 1970;120:527–30. Kakkar V.J., Kohen A.T., Edmondson R.A. et al. Low molecular weight vs standard heparin for prevention of venous thromboembo- lism after major abdominal surgery. Lancet. 1993;341(8840):259– 65. Kakkar A.K., Williamson R.C.N. Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost. 1999;25:239– 43. Levine M.N. Prevention of thrombotic disorders in cancer patients, undergoing chemotherapy. Thromb Haemost. 1997;78:133–6. Levine M.N., Lee A.Y. Treatment of venous thromboembolism in cancer patients. Semin Thromb Haemost. 1999;25:245–9. Luzzato G., Schafer A.L. The prethrombotic state in cancer. Semin Oncol. 1990;17:147–59. Prandoni P. Antithrombotic strategies in patients with cancer. Thromb Haemost. 1997;78(1):141–4. RasmussenM.C.,Wille-JorgensenP.,JorgensenL.N.Postoperative fatal pulmonary embolism in a general surgical department. Am J Surg. 1995;169:214–6. Roberts V.C., Cotton L.T. Prevention of postoperative deep vein thrombosis in patients with malignant disease. BMJ. 1974;1:358– 60. Rosenberg I.L., Evans M., Pollock A.V. Prophylaxis of postopera- tive leg vein thrombosis with low dose subcutaneous heparin or peroperative calf muscle stimulation: a controlled clinical trial. BMJ. 1975;1:649–51. Samama Ch.M., Samama M.M. Prevention of venous thrombo- embolism. Congress of European Society of Anaesthesiology. Am- sterdam, 1999. 39–43. The European Fraxiparin Study Group (EFSG). Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg. 1988;75(11):1058–63.
- 11 March 2019
- Published by Cifra Ltd - Russian Agency for Digital Standardization (RADS) in Тромбоз, гемостаз и реология
- No. 1,p. 43-66
The prevention and the treatment of venous thromboembolic complications in oncology (Textbook for students in higher education and in additional professional education)
Учебное пособие для обучающихся в системе высшего и дополнительного профессионального образования Учебное пособие используется для аудиторных занятий и самостоятельной работы студентов при изучении профилак- тики и лечения венозных тромбоэмболических осложнений у пациентов со злокачественными новообразованиями. Содержание освещает основные вопросы определения риска венозных тромбоэмболических осложнений и методы их профилактики и лечения у больных с местно-распространенными и метастатическими злокачественными новооб- разованиями. Учебное пособие предназначено для обучающихся в системе высшего образования (аспиранты, орди- наторы, интерны, студенты) и дополнительного профессионального образования (слушатели циклов повышения ква- лификации). Учебное пособие утверждено в качестве учебно-методического пособия Ученым советом ФГБУ «НМИЦ онкологии им. Н. Н. Петрова» МЗ РФ (протокол No 10 от 27.09.2016). ЛИТЕРАТУРА Российские клинические рекомендации по профилактике и лечению венозных тромбоэмболических осложнений у он- кологических пациентов. 2012. URL: http://www.phlebounion. ru/db.img/vte_in_oncology_final_04.05.2011.pdf. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Prac- tice Guideline Update. J Clin Oncol. 2013;31(17):2189–204. Mandala M., Falanga A., Roila F. Group EGW. Management of ve- nous thromboembolism (VTE) in cancer patients: ESMO Clin- ical Practice Guidelines. Ann Oncol. 2011;22(Suppl 6):vi85–92. Маджуга А.В., Сомонова О.В., Елизарова А.Л., Астахова В.М. ДВС-синдром в онкологии. Materia Medica. 1997;1(13):45–52. Российский Консенсус по профилактике послеоперацион- ных венозных тромбоэмболических осложнений. М.: Меди- цина, 2000. 20 с. Савельев В.С., Яблоков Ю.Г., Кириенко А.И. Тромбоэмболия легочной артерии. М.: Медицина, 1979. 264 с. Agnelli G. Venous Thromboembolism and cancer: two way clini- cal association. Thromb Haemost. 1997;78(1):117–20. Allan A., Williams J.T., Bolton J.P., LeQuesne L.P. The use of grad- uated compression stockings in the prevention ofpostoperative deep vein thrombosis. Brit J Surg. 1983;70:172–4. Bergqvist D., Burmark U.S., Flordal P.A. et al. Low molecular weight heparin started before surgery as prophylaxis against deep veine thrombosis: 2500 versus 5000 XaI units in 2070 patients. Brit J Surg. 1995;82:496–501. Chahinian A.P., Ware J.H., Zimmer U.N. Update on anticoagu- lation with warfarin and alternating chemotherapy in extensive small cell carcinoma of the lung (SCCL). Proc Am Soc Clin On- col. 1985;4:191. Kucher N., Koo S., Quiroz R. et al. Electronic Alerts to Prevent Venous Thromboembolism among Hospitalized Patients. N Engl J Med. 2005;352:969–77. Khorana A.A., Kuderer N.M., Culakova E. et al. Development and validation of a predictive model for chemotherapy-associ- ated thrombosis. Blood. 2008;111(10):4902–7. Bergqvist В., Agnelli G., Cohen A.T. et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Eng J Med. 2002;346:975–80. ENOXACAN Study Group «Efficacy and safety of Enoxaparin ver- sus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double blind randomized multicentre trial with venographic assessment». Brit J Surg. 1997;84:1099–103. FalangaA.,BarbuiT.,RicklesF.R.,LevineM.N.Guidelinesforclot- ting studies in cancer patients. Thromb Haemost. 1993;70:540–2. Gallus A.S. Prevention of post operative deep leg vein thrombosis in patients with cancer. Thromb Haemost. 1997;78:126–32. Gallus A., Cade J., Ockelford P. et al. Orgaran or heparin for prevention of venous thrombosis after elective surgery for malig- nant disease? A double blind randomized multicentre compari- son. Thromb Haemot. 1993;70:562–7. Green D., Hull R.D., Brant R., Pineo G.F. Lower mortality in cancer patients treated with low molecular weight versus standard heparin. Lancet. 1992;339(8804):1476. Green K.B., Silverstain R.L. Hypercoagulobility in cancer. Hematol Oncol Clin North Am. 1996;125:1–7. Hillen H.F. Thrombosis in cancer patients. Ann Oncol. 2000;11(Suppl 3):273–6. Kakkar V.V., Howe S.T., Nicolaides A.N. et al. Deep vein thrombosis of the leg: Is there a «high risk» group. Amer J Surg. 1970;120:527–30. Kakkar V.J., Kohen A.T., Edmondson R.A. et al. Low molecular weight vs standard heparin for prevention of venous thromboembo- lism after major abdominal surgery. Lancet. 1993;341(8840):259– 65. Kakkar A.K., Williamson R.C.N. Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost. 1999;25:239– 43. Levine M.N. Prevention of thrombotic disorders in cancer patients, undergoing chemotherapy. Thromb Haemost. 1997;78:133–6. Levine M.N., Lee A.Y. Treatment of venous thromboembolism in cancer patients. Semin Thromb Haemost. 1999;25:245–9. Luzzato G., Schafer A.L. The prethrombotic state in cancer. Semin Oncol. 1990;17:147–59. Prandoni P. Antithrombotic strategies in patients with cancer. Thromb Haemost. 1997;78(1):141–4. RasmussenM.C.,Wille-JorgensenP.,JorgensenL.N.Postoperative fatal pulmonary embolism in a general surgical department. Am J Surg. 1995;169:214–6. Roberts V.C., Cotton L.T. Prevention of postoperative deep vein thrombosis in patients with malignant disease. BMJ. 1974;1:358– 60. Rosenberg I.L., Evans M., Pollock A.V. Prophylaxis of postopera- tive leg vein thrombosis with low dose subcutaneous heparin or peroperative calf muscle stimulation: a controlled clinical trial. BMJ. 1975;1:649–51. Samama Ch.M., Samama M.M. Prevention of venous thrombo- embolism. Congress of European Society of Anaesthesiology. Am- sterdam, 1999. 39–43. The European Fraxiparin Study Group (EFSG). Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg. 1988;75(11):1058–63.